17 (47%) havde fået en behandling tidligere og 15 (42%) havde fået 2 eller flere forudgående behandlinger for RCC.
In the 25 mg arm (n = 36), all patients had metastatic disease; 4 (11%) had no prior chemo- or immunotherapy; 17 (47%) had one prior treatment, and 15 (42%) had 2 or more prior treatments for RCC.